BRIEF-Structure Therapeutics Announces Selection Of Lead Oral Small Molecule Amylin Receptor Agonist Accg-2671 For The Treatment Of Obesity

Reuters
18 Dec 2024
BRIEF-Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Selection Of Lead Oral Small Molecule Amylin Receptor Agonist Accg-2671 For The Treatment Of Obesity

Dec 17 (Reuters) - Structure Therapeutics Inc GPCR.O:

  • STRUCTURE THERAPEUTICS ANNOUNCES SELECTION OF LEAD ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY

  • STRUCTURE THERAPEUTICS INC - PHASE 1 STUDY OF ACCG-2671 EXPECTED TO START BY YEAR END 2025

Source text: ID:nGNXgRwDh

Further company coverage: GPCR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10